BioMarin Pharmaceutical Inc. agreed to pay up to $289 million for worldwide, ex-Asia Pacific rights to La Jolla Pharmaceutical Co.'s Riquent, despite the lupus drug's checkered past that includes Phase III failures, lost partners and regulatory setbacks. (BioWorld Today) Read More
